Jupiter Endovascular
Fred Ong currently serves as CFO at Jupiter Endovascular since 2025. Prior to this role, Ong held CFO positions at Sirona Medical from 2020 to 2024 and at Datavant from 2018 to 2019, where Datavant's technology aimed to connect health data while ensuring patient privacy, culminating in a $7 billion merger with Ciox Health. Ong co-founded Alara Systems Inc. and served as CFO from 2014 to 2017, focusing on machine learning technology for mammography. Earlier experience includes CFO and COO roles at U-Systems, successfully sold to GE Healthcare in 2012, and VP Finance positions at R2 Technology, sold to Hologic in 2006, and Mirapoint Inc., sold to Critical Path in 2010. Ong began a career in finance as a controller at ZeitNet Inc. and as a Sr. Audit Associate at PwC. Ong earned a Bachelor of Science in Business Administration from the University of California, Berkeley, Haas School of Business.
This person is not in any teams
This person is not in any offices
Jupiter Endovascular
Imagine a world where you could bring the precision and control of surgery to catheter-based therapies. For decades, endovascular procedures have been constrained by the technological limitations of catheters that lose stability and control within the anatomy. We have created a new class of therapies to overcome these constraints by using Endoportal Control to mimic the precision and control of direct surgical access, while maintaining the minimally invasive profile of an endovascular intervention. Our vision is big, spanning the breadth of cardiovascular disease where we see compelling opportunities to reimagine therapies for millions of patients. Jupiter Endovascular is a medical technology startup located in the San Francisco Bay Area, led by a team of successful medical device entrepreneurs. We have big ambitions, with a culture built on innovation, teamwork, and speed. We have raised capital from a diversified investor base, including venture capital, private equity, corporate strategic investors, and clinician angel investors.